\(
\def\WIPO{World Intellectual Property Organisation}
\)
Wobbling 35 U.S.C. § 112(A) Standards and their Impact on Antibody Patents
2024
Formats
| Format | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DataCite | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS | |
Title
Wobbling 35 U.S.C. § 112(A) Standards and their Impact on Antibody Patents
Author
Item Type
Journal article
Description
1 online resource
Note
The principle of the patent system is based on the concept of “quid pro quo”: an inventor gets protection for the invention they disclosed to the public. An inventor cannot claim protection for what they did not disclose. Thus, what is disclosed and whether such disclosure satisfies the requirements of the notice function is critical in determining the scope of patent claims. Although Section 112(a) provides the core requirements for a patent disclosure, it has historically been a relatively quiet area in terms of litigation. However, Section 112(a) is quickly turning into an area of hot debate because of rapid development in technological areas such as biotechnology, pharmaceutical, chemical, and computer-related industries, which has started to generate new questions that were not foreseen at the inception of the patent system. Furthermore, the different disclosure requirements applied in different jurisdictions make patent prosecution even more complex for multinational industries.
Source of Description
Crossref
Series
AIPLA Quarterly Journal, Spring 2024, Volume 52, Issue 2, p. 251.
Linked Resources
Published
[New York, NY] : Thomson Reuters, 2024.
Language
English
Copyright Information
https://1.next.westlaw.com/Copyright
Record Appears in